

Long-Term, Observational, Global Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies

First published: 19/02/2025

Last updated: 30/07/2025

Study

Ongoing

Administrative details

EU PAS number

EUPAS1000000478


Study ID

1000000478

DARWIN EU® study










No

Study countries

 Austria

 Canada

 China

-  France
 -  Germany
 -  Greece
 -  Italy
 -  Kuwait
 -  Saudi Arabia
 -  Türkiye
 -  United Arab Emirates
 -  United States
-

Study description

Brief Summary:

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

Detailed Description:

At the time of enrollment in the Registry, participant records will be queried for retrospective information about the participants' medical history and gMG disease treatment history. Following enrollment, prospective data collection will be performed using data obtained as part of the routine clinical care and through patient-reported outcome methods in use. Data will be collected using an electronic data capture system. The duration of data collection for the Registry will be up to 5 years from the day of enrollment.

Study status

Ongoing

Research institutions and networks

Institutions

Alexion Pharmaceuticals, Inc.

Contact details

Study institution contact

Alexion Pharmaceuticals, Inc Alexion Pharmaceuticals, Inc
clinicaltrials@alexion.com

Study contact

clinicaltrials@alexion.com

Primary lead investigator

N/A N/A

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 02/12/2019

Actual: 02/12/2019

Study start date

Planned: 02/12/2019

Actual: 02/12/2019

Date of final study report

Planned: 31/12/2029

Sources of funding

- Pharmaceutical company and other private sector

Study protocol

[ECU-MG-501 protocol final redacted 10Jul2019\(2\)_signed.pdf](#) (465.1 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

ClinicalTrials.gov ID: NCT04202341

Regulatory Agency Identifying Number(s): IND 101,219

<https://www.clinicaltrials.gov/study/NCT04202341>

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Drug utilisation

Effectiveness study (incl. comparative)

Evaluation of patient-reported outcomes

Hypothesis generation (including signal detection)

Safety study (incl. comparative)

Data collection methods:

Primary data collection

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Longitudinal observational registry

Study drug and medical condition

Medicinal product name

Study drug International non-proprietary name (INN) or common name
ECULIZUMAB

Anatomical Therapeutic Chemical (ATC) code
(L04AJ01) eculizumab
eculizumab

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

[Disease registry](#)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No